Nuvectis Pharma (NVCT) EBIT (2021 - 2026)

Nuvectis Pharma has disclosed EBIT across 6 years of filings, most recently posting -$6.3 million for Q1 2026.

• EBIT for Q1 2026 came in at -$6.3 million, down 12.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.3 million (down 34.48% YoY), and the FY2025 annual result was -$27.6 million, down 38.93% from the prior year.
• EBIT came in at -$6.3 million for Q1 2026 at Nuvectis Pharma, up from -$7.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$2.9 million in Q1 2022 to a low of -$7.8 million in Q3 2025.
• The 5-year median for EBIT is -$5.9 million (2022), against an average of -$5.6 million.
• Peak annual rise in EBIT reached 39.83% in 2022, while the deepest fall reached 12704.35% in 2022.
• Nuvectis Pharma's EBIT stood at -$6.8 million in 2022, then dropped by 1.3% to -$6.9 million in 2023, then rose by 6.07% to -$6.4 million in 2024, then decreased by 18.11% to -$7.6 million in 2025, then grew by 17.82% to -$6.3 million in 2026.
• The last three EBIT figures came in at -$6.3 million (Q1 2026), -$7.6 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.